Genelabs Withdraws Prasterone Application In Europe; U.S. Confirmatory Trial Stays On Schedule
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is seeking a partner for Europe to assist in future regulatory discussions after data were deemed insufficient. An additional U.S. trial confirming prasterone's effects on bone loss is expected to be complete by year-end.
You may also be interested in...
Genelabs' Prestara Phase III Does Not Confirm Bone Mineral Density Effect
The trial was designed to meet FDA's "approvable" letter request for confirmation of bone mineral density increases in women with lupus receiving glucocorticoids. Genelabs plans to meet with the agency when it completes data analysis.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.